Confirmed but Not Covered: The Insurance Logic That Accepts Your Diagnosis and Rejects Your Treatment

The letter from the insurance company arrived three weeks after Sandra, a 47-year-old schoolteacher in North Carolina, received a confirmed diagnosis of relapsing-remitting multiple sclerosis. Her neurologist had recommended a disease-modifying therapy — a medication with a well-established evidence base and a prominent place in national clinical guidelines for her specific condition. The insurer's response was unambiguous: the treatment was not medically necessary.

The diagnosis was not in dispute. The condition was acknowledged. The recommended treatment was, by every published standard, the appropriate clinical response. And yet the insurer had drawn an invisible line between accepting the diagnosis and accepting any obligation to pay for what the diagnosis required.

This pattern is neither rare nor accidental. It reflects a deliberate architecture within insurance contract language that separates the act of acknowledging a condition from the obligation to fund its treatment — and it affects patients across virtually every diagnostic category.

How Insurers Separate Diagnosis from Obligation

The mechanism that enables this contradiction is embedded in the phrase 'medically necessary' — a term that appears in nearly every insurance contract in the United States and is defined, in each case, by the insurer itself.

Most plans define medical necessity not simply as care that a physician has recommended, but as care that meets the insurer's own internal criteria: that it is consistent with the insurer's clinical guidelines, that it cannot be safely replaced by a less expensive alternative, and that it is not considered experimental or investigational under the insurer's classification system.

This definition grants the insurer significant latitude. A physician may determine that a specific biologic medication is the appropriate first-line treatment for a patient's confirmed autoimmune condition. The insurer may simultaneously determine that the patient has not yet tried and failed a series of older, cheaper medications — a process known as step therapy — and that the biologic therefore does not meet its internal criteria for medical necessity. The diagnosis is accepted. The recommended treatment is denied.

The insurer is not claiming the patient is not sick. It is claiming the patient has not yet been sick in the specific sequence the insurer prefers.

The Clinical Guideline Mismatch

One of the most common mechanisms behind treatment denial for confirmed diagnoses is a divergence between the clinical guidelines relied upon by the treating physician and the clinical criteria embedded in the insurer's own coverage policies.

National specialty societies — including the American College of Rheumatology, the American Academy of Neurology, and the American Diabetes Association — publish evidence-based treatment guidelines that physicians use to inform their recommendations. These guidelines reflect the current state of clinical research and are updated regularly.

Insurers develop their own coverage criteria through internal medical policy teams, often using guidelines published by organizations such as MCG Health (formerly Milliman Care Guidelines) or InterQual. These commercial criteria are not always synchronized with the most current specialty society recommendations, and in some cases they lag behind the published evidence by years.

When a physician's recommendation is grounded in the most current specialty guidelines and an insurer's denial is grounded in an older or more restrictive commercial criteria set, the patient is caught between two parallel clinical universes — one populated by their doctor, the other populated by the insurer's internal review team.

The Contractual Language That Creates the Gap

Beyond medical necessity definitions, insurance contracts contain several additional provisions that insurers use to separate diagnosis acceptance from treatment obligation.

Exclusion clauses identify specific treatments, devices, or drug categories that are excluded from coverage regardless of the underlying diagnosis. A patient with a confirmed diagnosis of chronic pain may find that the most effective treatment for their condition — a specific neuromodulation device, for example — appears on an exclusion list that was never prominently disclosed during enrollment.

Experimental and investigational designations allow insurers to deny coverage for treatments that have received FDA approval and are recommended in clinical guidelines but have not yet accumulated the volume of published randomized controlled trial data the insurer requires for its own coverage determination. This designation is applied inconsistently and is frequently contested in appeals.

Coverage tiers and formulary restrictions in pharmacy benefits can effectively deny access to a prescribed medication not through an outright denial but through cost-sharing so prohibitive that the patient cannot afford to fill the prescription. A medication placed on a specialty tier may carry a monthly cost-sharing obligation of several hundred dollars even after the deductible is met.

Documented Patterns Across Diagnostic Categories

Patient advocacy organizations, academic researchers, and investigative journalists have documented the diagnosis-treatment gap across a wide range of conditions. Patients with confirmed diagnoses of rheumatoid arthritis frequently face step therapy requirements before accessing biologic therapies their physicians consider first-line. Patients with confirmed major depressive disorder encounter prior authorization barriers for transcranial magnetic stimulation, a non-pharmacological treatment with robust evidence and FDA clearance. Patients with confirmed obstructive sleep apnea are denied CPAP supplies under coverage criteria that impose documentation requirements their physicians were never informed existed.

In each case, the diagnosis is on record. The clinical recommendation is documented. The insurer's denial does not challenge either. It simply inserts a procedural or contractual barrier between the two.

Forcing Consistency: A Step-by-Step Approach

When a patient's treatment is denied for a condition the insurer has already acknowledged, the appeal strategy should be built around a single core argument: internal consistency. The insurer cannot simultaneously accept the diagnosis and deny the treatment that its own clinical guidelines — or the prevailing clinical consensus — associate with that diagnosis.

Step one: Obtain the denial in writing. Request the full denial letter, including the specific clinical criteria used to evaluate the claim, the name of the reviewing clinician, and the insurer's internal medical policy number cited in the decision. This information is available upon request and is essential for building an appeal.

Step two: Request the insurer's clinical coverage criteria. Most insurers are required to provide, upon request, the specific clinical guidelines or coverage policies used to evaluate a medical necessity determination. Compare these criteria against the most current guidelines published by the relevant national specialty society. Document any discrepancies.

Step three: Secure a detailed letter of medical necessity from the treating physician. This letter should explicitly address the insurer's stated denial rationale, cite current clinical guidelines supporting the recommended treatment, and explain why alternative treatments are clinically inappropriate for this specific patient. Generic letters of necessity are rarely sufficient. The letter must respond point-by-point to the insurer's criteria.

Step four: Invoke the diagnosis-treatment consistency argument. In the written appeal, state explicitly that the insurer's coverage determination is internally inconsistent: the plan has acknowledged the diagnosis on record, the recommended treatment is the standard of care for that diagnosis as established by [specific guideline source and publication date], and no clinically appropriate alternative exists that meets the insurer's own criteria for medical necessity.

Step five: Request a peer-to-peer review. Most insurers offer a mechanism by which the treating physician can speak directly with the insurer's medical reviewer. This conversation frequently results in reversal, particularly when the treating physician can demonstrate that the reviewer's criteria are outdated or misapplied.

Step six: Escalate to external review. If the internal appeal is unsuccessful, request an independent external review. Under federal law, most plans must offer this option for medical necessity denials. External reviewers apply clinical standards rather than the insurer's internal criteria and overturn insurer decisions at a meaningful rate.

The Principle at Stake

The gap between diagnosis and treatment coverage is not a billing anomaly or a clerical error. It is a structural feature of how insurance contracts are written and how medical necessity determinations are administered. Patients who understand this structure — and who know how to document the inconsistency and force the insurer to defend it — are in a substantially stronger position than those who accept the first denial as final.

A confirmed diagnosis is not merely a label. It is a clinical finding that carries with it a body of evidence about appropriate care. Patients have every right to insist that their insurer engage with that evidence — and to demand that the plan's coverage decisions reflect the same medical reality their physician has already confirmed.